GLOBUS MEDICAL INC(GMED)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
GLOBUS MEDICAL INC (GMED) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GMED at 79.5/100 on a 32-signal composite quality model, placing it at rank #37 of 2,960 stocks — the top 5% of the AI-ranked universe. GMED scores in the top quartile across institutional flow (88.3), revenue growth (86.8), balance sheet strength (85.9). Shareholder dilution risk is elevated at 43.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GLOBUS MEDICAL INC reports quarterly revenue of $789.6M, net income of $151.6M, an operating margin of 23.1%. Top institutional holders of GMED by reported 13-F value include BlackRock, Jupiter Topco, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GMED trades on the NYSE exchange and files with the SEC under CIK 1237831. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GLOBUS MEDICAL INC directly from SEC EDGAR.
AI Quality Score
79.5/100
AI Rank
#37
Revenue
$789.6M
Net Income
$151.6M
Free Cash Flow
$176.6M
Operating Margin
23.1%
GMED key financials by period
GLOBUS MEDICAL INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$2.9B
$537.9M
16.3%
FY 2024
10-K
$2.5B
$103.0M
6.6%
FY 2023
10-K
$1.6B
$122.9M
8.5%
FY 2022
10-K
$1.0B
$190.2M
22.3%
FY 2021
10-K
$958.1M
$149.2M
17.9%
FY 2020
10-K
$789.0M
$102.3M
14.1%
Institutions holding GMED
Institutional investors reporting a position in GLOBUS MEDICAL INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 net sales rose 5.9% to $789.6M and operating income jumped to $182.4M from $76.1M, but net income fell to $151.6M absent last year's $110.6M bargain purchase gain.
Biggest Revenue Drivers
Musculoskeletal Solutions$763.5M
U.S. Musculoskeletal Solutions sales rose $45.7M, driven by spine implantable devices of $32.3M and neuromonitoring of $10.4M; international added $21.2M
Enabling Technologies$26.1M
Domestic Enabling Technology sales decreased $12.3M, driven by lower unit placement; international rose $3.2M on increased unit placement
Biggest Revenue Drivers
Total revenue: $789.6M+5.9% YoY
Musculoskeletal Solutions$763.5M
U.S. Musculoskeletal Solutions sales rose $45.7M, driven by spine implantable devices of $32.3M and neuromonitoring of $10.4M; international added $21.2M
Enabling Technologies$26.1M
Domestic Enabling Technology sales decreased $12.3M, driven by lower unit placement; international rose $3.2M on increased unit placement
Largest Expense Items
Selling, general and administrative$286.8M-5.5% YoY
Decrease of $19.0M in employee-related expenses, partially offset by a $2.7M increase in provision for litigation
Cost of sales (exclusive of amortization of intangibles)$241.4M-2.9% YoY
Prior-year Nevro inventory step-up amortization of $6.0M and $7.3M lower product costs, offset by $3.5M higher freight
Research and development$36.3M-9.1% YoY
Driven by a $4.0M decrease in employee-related expenses
Amortization of intangibles$29.6M-2.1% YoY
Primarily driven by the finalization of amortization of intangible assets
Margins: Cost of sales fell to 30.6% of net sales from 33.4%, and SG&A to 36.3% from 40.7%, lifting operating income to $182.4M from $76.1M.
Watch Items from the Filing
Enabling Technologies net sales fell to $26.1M from $35.2M; domestic Enabling Technology sales dropped $12.3M on lower unit placement.
U.S. net sales grew only 3.0% to $619.1M while international grew 18.0% to $170.5M; U.S. Nevro sales declined $15.1M.
Pimenta litigation: November 2025 jury verdict of $28.7M in damages; $43.1M liability accrued at December 31, 2025, with appeal filed.
Effective tax rate rose to 20.1% from (7.8%), reflecting prior-period state valuation allowance release and non-taxable bargain purchase gain.
Repurchased 1.6 million shares for $136.1 million at an average $82.96; $253.9 million remains authorized, with no borrowings under the $400.0 million facility.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
